Hong Kong Stock Market Flash | EVEREST MED Surges Over 5% in Morning Trade as China Approves NDA for PSVT Indication

Stock News

Sep 08

EVEREST MED (01952) saw its share price climb more than 5% during morning trading on Wednesday. As of the time of writing, the stock was up 4.73% to HK$32.78, with trading turnover reaching HK$151 million.

The surge came after the company announced on September 3 that China's National Medical Products Administration (NMPA) had approved the New Drug Application (NDA) for Xintuo (etripamil nasal spray). The drug is indicated for the acute symptomatic treatment of paroxysmal supraventricular tachycardia (PSVT) in adults, converting the condition to sinus rhythm.

Xintuo had previously received approval from the U.S. Food and Drug Administration (FDA) in December 2025, making it the first and only innovative therapy approved in over 30 years for acute symptomatic episodes of PSVT in adults. With this latest approval in China, the innovative treatment has officially entered the Chinese market, marking the first approved product for EVEREST MED in the cardiovascular disease field.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.atigrnexa.com/news/1167357330"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1167357330\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1167357330?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-09-08 11:56","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1167357330","market":"us","top_or_hot":-1,"title":"Hong Kong Stock Market Flash | EVEREST MED Surges Over 5% in Morning Trade as China Approves NDA for PSVT Indication","media":"Stock News","content":"<p><b>EVEREST MED</b> (01952) saw its share price climb more than 5% during morning trading on Wednesday. As of the time of writing, the stock was up 4.73% to HK$32.78, with trading turnover reaching HK$151 million.<br><br>The surge came after the company announced on September 3 that China's National Medical Products Administration (NMPA) had approved the New Drug Application (NDA) for Xintuo (etripamil nasal spray). The drug is indicated for the acute symptomatic treatment of paroxysmal supraventricular tachycardia (PSVT) in adults, converting the condition to sinus rhythm.<br><br>Xintuo had previously received approval from the U.S. Food and Drug Administration (FDA) in December 2025, making it the first and only innovative therapy approved in over 30 years for acute symptomatic episodes of PSVT in adults. With this latest approval in China, the innovative treatment has officially entered the Chinese market, marking the first approved product for <b>EVEREST MED</b> in the cardiovascular disease field.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Hong Kong Stock Market Flash | EVEREST MED Surges Over 5% in Morning Trade as China Approves NDA for PSVT Indication</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHong Kong Stock Market Flash | EVEREST MED Surges Over 5% in Morning Trade as China Approves NDA for PSVT Indication\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2026-09-08 11:56</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><b>EVEREST MED</b> (01952) saw its share price climb more than 5% during morning trading on Wednesday. As of the time of writing, the stock was up 4.73% to HK$32.78, with trading turnover reaching HK$151 million.<br><br>The surge came after the company announced on September 3 that China's National Medical Products Administration (NMPA) had approved the New Drug Application (NDA) for Xintuo (etripamil nasal spray). The drug is indicated for the acute symptomatic treatment of paroxysmal supraventricular tachycardia (PSVT) in adults, converting the condition to sinus rhythm.<br><br>Xintuo had previously received approval from the U.S. Food and Drug Administration (FDA) in December 2025, making it the first and only innovative therapy approved in over 30 years for acute symptomatic episodes of PSVT in adults. With this latest approval in China, the innovative treatment has officially entered the Chinese market, marking the first approved product for <b>EVEREST MED</b> in the cardiovascular disease field.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4588","symbol_name":"碎股","start_time":0,"source_url":"","article_id":"1167357330","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1167357330","pubTimestamp":1788839775,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"EVEREST MED (01952) saw its share price climb more than 5% during morning trading on Wednesday. As of the time of writing, the stock was up 4.73% to HK$32.78, with trading turnover reaching HK$151...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4588":"碎股","BK1161":"生物科技","BK4585":"ETF&股票定投概念","BK1574":"生物医药B类股","IPOS":"Renaissance International IPO ETF","VXUS":"国际股票ETF-Vanguard","KCAI":"KraneShares China Alpha Index ETF","BK1583":"高瓴概念","01952":"云顶新耀"},"translate_title":"港股快讯 | 中国批准PSVT适应症NDA，EVEREST MED早盘大涨逾5%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"01952":1,"KCAI":1,"IPOS":1,"VXUS":1},"content_text":"EVEREST MED (01952) saw its share price climb more than 5% during morning trading on Wednesday. As of the time of writing, the stock was up 4.73% to HK$32.78, with trading turnover reaching HK$151 million.The surge came after the company announced on September 3 that China's National Medical Products Administration (NMPA) had approved the New Drug Application (NDA) for Xintuo (etripamil nasal spray). The drug is indicated for the acute symptomatic treatment of paroxysmal supraventricular tachycardia (PSVT) in adults, converting the condition to sinus rhythm.Xintuo had previously received approval from the U.S. Food and Drug Administration (FDA) in December 2025, making it the first and only innovative therapy approved in over 30 years for acute symptomatic episodes of PSVT in adults. With this latest approval in China, the innovative treatment has officially entered the Chinese market, marking the first approved product for EVEREST MED in the cardiovascular disease field.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}